Medesis Pharma (STU:76D) Change In Receivables : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Medesis Pharma Change In Receivables?

Medesis Pharma's change in receivables for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Medesis Pharma's Accounts Receivable stayed the same from Dec. 2023 to Jun. 2024 .

Medesis Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Medesis Pharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Medesis Pharma's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medesis Pharma's Days Sales Outstanding for the six months ended in Jun. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medesis Pharma's liquidation value for the six months ended in Jun. 2024 was €-7.10 Mil.

Medesis Pharma Change In Receivables Historical Data

The historical data trend for Medesis Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma Change In Receivables Chart

Medesis Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Medesis Pharma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial						-	-	-	-	-

Medesis Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Medesis Pharma (STU:76D) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medesis Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.031	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Medesis Pharma's accounts receivable are only considered to be worth 75% of book value:

Medesis Pharma's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.025	-	7.202	+	0.75 * 0	+	0.5 * 0.161
=	-7.10

Medesis Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medesis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (STU:76D) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALMDP:France 76D:Germany

Address

Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670

Website

https://www.medesispharma.com

Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines